New method for the early detection of Calcific Aortic Valve Disease (CAVD)
There is an unmet medical need of finding reliable methods for the diagnosis of calcific aortic valve disease (CAVD) at early stages. Approximately 2–4 % of people aged over 65 will develop CAVD, and 25 % of individuals in this age group with disease symptoms, have a 50 % increased risk of cardiovascular related events. Moreover, there is an associated risk of 80 % of progression over 5 years, to heart failure, aortic valve replacement or death. The early diagnosis of CAVD by detecting aortic valve calcification could allow us to improve patient´s clinical management.
CNIC researchers have identified four differentially expressed genes whose circulating expression levels can determine if a subject is suffering from aortic valve calcification, either in a clinical or subclinical stage. These genes can also be used for the differential diagnosis between CAVD and subclinical aortic-valve calcification. Diagnosis/biotech companies are sought for a license agreement.NumberEP20382121Priority date20/02/2020ApplicantsCNICInventorsDonal MacGrogan, Fátima Sánchez Cabo, Leticia Fernández Friera, José Luis de la Pompa